The emerging role of fusion inhibitors in HIV infection.

被引：14

作者：

De Clercq E. ^{[1
]}

机构：

[1] Rega Institute for Medical Research, Katholieke Universiteit Leuven

来源：

Drugs in R & D | 1999年 / 2卷 / 5期

关键词：

Human Immunodeficiency Virus; Adis International Limited; Human Immunodeficiency Virus Infection; Human Immunodeficiency Virus Replication; CXCR4 Antagonist;

D O I：

10.2165/00126839-199902050-00010

中图分类号：

学科分类号：

摘要：

Fusion of HIV with its host cell requires the interaction of the viral envelope glycoprotein 120 (gp120) with the chemokine receptor CXCR4 [T cell-tropic (T-tropic) or X4 HIV strains] or CCR5 [macrophage-tropic (M-tropic) or R5 HIV strains] followed by a 'spring-loaded' action of the glycoprotein 41 (gp41) that ensures fusion of the viral and cellular lipid membranes and permits the viral nucleocapsid to enter the cell. The overall fusion process can be blocked by a number of compounds. These include siamycin analogues, SPC 3 (a synthetic peptide derived from the V3 domain of gp120), pentafuside (T 20, DP 178) [a synthetic peptide corresponding to amino acid residues 127 to 162 of gp41], the betulinic acid derivative RPR 103611, TAK 779 (a low molecular weight non-peptide CCR5 antagonist) and a number of compounds (T 22, T 134, ALX40-4C, CGP64222 and AMD 3100) that are targeted at the CXCR4 receptor. In particular, the bicyclam AMD 3100 has proved highly potent and selective as a CXCR4 antagonist that blocks the infectivity of X4 HIV strains in the nanomolar concentration range. The proof-of-concept that fusion inhibitors should be able to suppress viral replication in vivo has been demonstrated with pentafuside. Pentafuside and AMD 3100 have now proceeded to phase II clinical trials.

引用

页码：321 / 331

页数：10

共 127 条

[21] Friedrichs MS(1994)Determinants of human immunodeficiency virus type 1 resistance to gp41-derived inhibitory peptides Proc Natl Acad Sci U S A 91 3564-8
[22] Detlefsen D(1999)Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry Proc Natl Acad Sci U S A 96 5698-703
[23] Chokekijchai S(1992)Triterpene derivatives that block entry of human immunodeficiency virus type 1 into cells Antimicrob Agents Chemother 36 1249-55
[24] Kojima E(1992)A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity Biochem Biophys Res Commun 189 845-50
[25] Anderson S(1994)Anti-human immunodeficiency virus activity of a novel synthetic peptide, T22 ([Tyr-5,12, Lys-7]polyphemusin II): a possible inhibitor of virus-cell fusion Biochem Biophys Res Commun 205 1729-35
[26] Nakashima H(1998)Anovel anti-HIV synthetic peptide, T-22 ([Tyr5,12, Lys7]-polyphemusin II) Bioorg Med Chem 6 231-8
[27] Ichiyama K(1997)Structure-activity relationships of an anti-HIV peptide, T22 J Exp Med 186 1389-93
[28] Inazawa K(1999)Effective lowly cytotoxic analogs of an HIV-cell fusion inhibitor, T22 ([Tyr5,12, Lys7]-polyphemusin II) J Virol 73 1719-23
[29] Lin P-F(1996)A small molecule CXCR4 inhibitor that blocks T cell line-tropic HIV-1 infection J Virol 70 2825-31
[30] Samanta H(1997)T134, a smallmolecule CXCR4 inhibitor, has no cross-drug resistance with AMD3100, a CXCR4 antagonist with a different structure J Exp Med 186 1395-400

← 1 2 3 4 5 6 7 8 9 10 →